Clinical Trial Update: ARRY-380 + Trastuzuamab for Breast w/ Brain Mets [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ARRY-380 in combination with trastuzumab for brain metastases in HER2-positive breast cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• ARRY-380
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Brain Metastases From HER2 and Breast Cancer, Advanced HER2-positive Breast Cancer | Phase 1 | Status: COMPLETED